The report provides a detailed analysis essential for establishing a Retapamulin production plant. It encompasses all critical aspects necessary for Retapamulin production, including the cost of Retapamulin production, Retapamulin plant cost, Retapamulin production costs, and the overall Retapamulin production plant cost. Additionally, the study covers specific expenditures associated with setting up and operating a Retapamulin production plant. These encompass production processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.
Retapamulin is an FDA-approved synthetic chemical compound that serves as a topical antibiotic. It is widely utilized for the treatment of various skin infections due to its significant antibacterial activity against various strains, including methicillin and mupirocin-resistant Staphylococcus aureus. Moreover, it also finds its application as a topical ointment for the treatment of a huge variety of bacterial skin infections.
The market for Retapamulin is largely driven by its application as a broad-spectrum antibiotic with no cross-resistance to other existing classes of antibiotics, which significantly boosts its demand in the medical industry. Moreover, its employment as a topic treatment for various skin infections due to its potential activity against a broad range of bacteria further enhances its demand in the medical, healthcare, and pharmaceutical industries. Overall, multiple factors, including the availability of raw material (Pleuromutilin), its cost, quality standards, and sustainability practices, significantly influence industrial Retapamulin procurement to a large extent.
Raw Material for Retapamulin Production
According to the Retapamulin production plant project report, the major raw material for Retapamulin production includes Pleuromutilin.
Production Process of Retapamulin
The extensive Retapamulin production cost report consists of the following industrial production process:
- Production via Biosynthesis: This method of production involves a semi-synthetic process that utilizes naturally occurring pleuromutilin for producing Retapamulin as the product. The process is initiated by the tosylation (addition of the p-toluenesulfonyl group) of pleuromutilin by using tosyl chloride, followed by a reaction with thiourea, which produces thiourea ester. Further, the thiourea ester undergoes hydrolysis to give the thiol, followed by its utilization to substitute tropine mesylate, which results in the formation of Retapamulin as the final product.
Retapamulin is a compound that belongs to the class of pleuromutilin. It is the first pleuromutilin approved for human use. Moreover, the compound is a carbotricyclic compound with a density of 1.16 g/cm3. The molecular formula of the compound is C30H47NO4S, and its molar mass is 517.76 g/mol. Additionally, the boiling point of the compound is 594.9°C, and it does not dissolve in water. Its solubility in ethanol is 114.8 mg/mL and 16.15 mg/mL in DMSO. The compound is mainly marketed under the brand name Altabax. It may have some potential side effects, which include headache, diarrhea, nausea, and nasopharyngitis.